PCTH: A novel orally active chelator for the treatment of iron overload disease

Hemoglobin

Volumn 30, Issue 1, 2006, Pages 93-104

  Lovejoy, David B ^a   Kalinowski, Danuta ^a   Bernhardt, Paul V ^b   Richardson, Des R ^a  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Desferrioxamine (DFO); Iron (Fe); Iron chelators; PCTH; Pyridoxal isonicotinoyl hydrazone (PIH)

Indexed keywords

2 PYRIDYLCARBOXALDEHYDE 2 THIOPHENECARBOXYL HYDRAZONE; DEFERIPRONE; HYDRAZONE DERIVATIVE; IRON CHELATING AGENT; PHENIPRAZINE; UNCLASSIFIED DRUG;

BETA THALASSEMIA; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; FRIEDREICH ATAXIA; HUMAN; IRON KINETICS; IRON OVERLOAD; IRON TRANSPORT; MITOCHONDRION; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDRAZONES; IRON CHELATING AGENTS; IRON OVERLOAD; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDINES;

ANIMALIA; ATAXIA;

EID: 33645091614     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260500455367     Document Type: Conference Paper

References (26)

1. Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 2003; 73(3):200-210.
2. Kalinowski D, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005; 57(4):547-883.
3. Weatherall DJ. The iron-loading anemias. In: Martell AE, Anderson WF, Badman DG, eds. Development of Iron Chelators for Clinical Use. New York: Elsevier-North Holland, 1981; 3-12.
4. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89(3):739-761.
5. Hoffbrand AV, Pettit JE, Moss PAH. Genetic disorders of hemoglobin. In: Hoffbrand AV, Pettit JE, Moss PAH, eds. Essential Haematology, 4th ed. London: Blackwell Scientific Publishers, 2001; 71-83.
6. Wong C, Richardson DR. β-Thalassaemia: emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol 2003; 35(7):1144-1149.
7. Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol 1999; 56(10):1201-1208.
8. Puccio H, Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 2000; 9(6):887-892.
9. Richardson DR. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Investig Drugs 2003; 12(2):235-245.
10. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 2005; 105(5):1867-1874.
11. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000; 95(9):2776-2779.
12. Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16):2161-2183.
13. Becker E, Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 1999; 134(5):510-521.
14. Richardson DR, Becker E, Bernhardt PV. The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoylhydrazone, 2- pyridylcarboxaldehyde benzoylhydrazone monohydrate and 2-furaldehyde isonicotinoylhydrazone. Acta Crystallogr C 1999; 55(pt 12):2102-2105.
15. Richardson DR, Bernhardt P, Becker E. Iron Chelators and Uses Thereof. International Publication No. WO 01/ 17530, 2000.
16. Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoylhydrazone as a new iron chelating agent. FEBS Lett 1979; 97(2):317-321.
17. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 1979; 586(2):278-297.
18. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 1998; 131(4):306-315.
19. Bernhardt PV, Chin P, Richardson DR. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron (III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J Biol Inorg Chem 2001; 6(8):801-809.
20. Richardson DR, Ponka P. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 1994; 124(5):660-671.
21. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995: 86(11):4295-4306.
22. Wong CS, Kwok JC, Richardson DR. The novel iron chelator, 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, is orally active and induces iron excretion in mice. Biochim Biophys Acta 2004; 1739(1):70-80.
23. Richardson DR, Mouralian C, Ponka P, Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 2001; 1536(2-3):133-140.
24. Ponka P, Wilczynska A, Schulman HM. Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor or heme synthesis. Biochim Biophys Acta 1982; 720(1):96-105.
25. Adams ML, Ostapiuk I, Grasso JA. The effects of inhibition of heme synthesis on the intracellular localization of iron in rat reticulocytes. Biochim Biophys Acta 1989; 1012(3):243-253.
26. Richardson DR, Ponka P, Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood 1996; 87(8):3477-3488.